TheraVet SA

ALVET

BE0974387194

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 07:11:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.79 ^EUR	+1.54%		+1.28%	-45.52%

Apr. 23	TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 13	TheraVet SA Announces the Launch of BIOCERA-VET Equine	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about TheraVet SA

TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
TheraVet SA Announces the Launch of BIOCERA-VET Equine	Mar. 13	CI
TheraVet’s Veterinary Medicinal Product Gets Patents in Europe, Singapore, Israel	Jan. 30	MT
Global markets live: Charles Schwab, Apple, Spirit Airlines, BP, Visa...	Jan. 17
TheraVet SA Announces Commercial Launch of Biocera-VET in Germany	Jan. 17	CI
Global markets live: Boeing, GSK, Hays, Shell, Eli Lilly...	Jan. 09
TheraVet Announces Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy	Jan. 09	CI
TheraVet: positive feedback in canine osteosarcoma	Jan. 04	CF
TheraVet launches osteosarcoma study	Nov. 23	CF
TheraVet SA Announces Launch of Biocera-Vet Canine Osteosarcoma Study Conducted by the University of Florida	Nov. 23	CI
TheraVet Sets Up EUR3 Million Equity-linked Funding Facility	Nov. 21	MT
TheraVet SA announced that it expects to receive ?1 million in funding	Nov. 19	CI
Vet Biotech TheraVet Names CFO	23-10-25	MT
TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer	23-10-25	CI
TheraVet Recruits Patients for Study on Bone Substitute Use in Dog Revision Surgery	23-09-27	MT
TheraVet SA Announces Patient Recruitment Phase Successfully Completed in Biocera-Vet Fracture Revision Surgery Study in Toy Dogs	23-09-27	CI
TheraVet: financing secured until mid-2024	23-09-06	CF
TheraVet SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-06	CI
TheraVet: growing interest in canine osteosarcoma	23-06-15	CF
TheraVet: new commercial launch, share price rises	23-05-31	CF
TheraVet SA Announces the Commercial Launch of A Local and Sustained Antibiotic Releasing Bone Substitute	23-05-31	CI
TheraVet SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
TheraVet Kicks Off Reference Program for Bone Cancer in Dogs	23-04-06	MT
TheraVet: international distribution agreement	23-02-21	CF
Theravet Signs Global Distribution Deal for Bone Substitutes for Dogs; Shares Up 52%	23-02-21	MT

TheraVet SA is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets. At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERAVET SA	-45.52%	2.72M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B